Stem Cells Derived from Amniotic Fluid

Mara Cananzi, Anthony Atala, Paolo de Coppi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In this chapter, we provide an overview of the potential advantages and disadvantages of different stem and progenitor cell populations identified to date in amniotic fluid, along with their properties and potential clinical applications. In the last ten years, placenta, fetal membranes (i.e., amnion and chorion), and amniotic fluid have been investigated as potentially uncontroversial sources of stem cells. Such tissues are typically discarded after delivery or are accessible during pregnancy through amniocentesis and chorionic villus sampling. Cell populations having multilineage differentiation potential and immunomodulatory properties have been isolated from the human placenta and fetal membranes, including human amniotic epithelial cells (hAECs), human amniotic mesenchymal stromal cells (hAMSCs), human chorionic mesenchymal stromal cells (hCMSCs), and human chorionic trophoblastic cells (hCTCs). From amniotic fluid (AF), two stem cell populations have been isolated: amniotic fluid mesenchymal stem cells (AFMSCs) and amniotic fluid stem (AFS) cells. It is possible that these cells may, given the easier accessibility of AF in comparison with other extra-embryonic tissues, hold much promise in regenerative medicine.

Original languageEnglish (US)
Title of host publicationEssentials of Stem Cell Biology: Third Edition
PublisherElsevier Inc.
Pages141-156
Number of pages16
ISBN (Print)9780124104273, 9780124095038
DOIs
StatePublished - Nov 4 2013
Externally publishedYes

Fingerprint

Amniotic Fluid
Stem Cells
Mesenchymal Stromal Cells
Extraembryonic Membranes
Placenta
Chorionic Villi Sampling
Population
Chorion
Amnion
Regenerative Medicine
Amniocentesis
Epithelial Cells
Pregnancy

Keywords

  • Amniotic fluid
  • Cell surface antigens
  • Fetal origin
  • Hematopoietic progenitor cells
  • Mesenchymal stem cells
  • Multilineage potential
  • Transcriptome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cananzi, M., Atala, A., & de Coppi, P. (2013). Stem Cells Derived from Amniotic Fluid. In Essentials of Stem Cell Biology: Third Edition (pp. 141-156). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-409503-8.00011-1

Stem Cells Derived from Amniotic Fluid. / Cananzi, Mara; Atala, Anthony; de Coppi, Paolo.

Essentials of Stem Cell Biology: Third Edition. Elsevier Inc., 2013. p. 141-156.

Research output: Chapter in Book/Report/Conference proceedingChapter

Cananzi, M, Atala, A & de Coppi, P 2013, Stem Cells Derived from Amniotic Fluid. in Essentials of Stem Cell Biology: Third Edition. Elsevier Inc., pp. 141-156. https://doi.org/10.1016/B978-0-12-409503-8.00011-1
Cananzi M, Atala A, de Coppi P. Stem Cells Derived from Amniotic Fluid. In Essentials of Stem Cell Biology: Third Edition. Elsevier Inc. 2013. p. 141-156 https://doi.org/10.1016/B978-0-12-409503-8.00011-1
Cananzi, Mara ; Atala, Anthony ; de Coppi, Paolo. / Stem Cells Derived from Amniotic Fluid. Essentials of Stem Cell Biology: Third Edition. Elsevier Inc., 2013. pp. 141-156
@inbook{5591f62ea04d4cd89503300ffd5494c0,
title = "Stem Cells Derived from Amniotic Fluid",
abstract = "In this chapter, we provide an overview of the potential advantages and disadvantages of different stem and progenitor cell populations identified to date in amniotic fluid, along with their properties and potential clinical applications. In the last ten years, placenta, fetal membranes (i.e., amnion and chorion), and amniotic fluid have been investigated as potentially uncontroversial sources of stem cells. Such tissues are typically discarded after delivery or are accessible during pregnancy through amniocentesis and chorionic villus sampling. Cell populations having multilineage differentiation potential and immunomodulatory properties have been isolated from the human placenta and fetal membranes, including human amniotic epithelial cells (hAECs), human amniotic mesenchymal stromal cells (hAMSCs), human chorionic mesenchymal stromal cells (hCMSCs), and human chorionic trophoblastic cells (hCTCs). From amniotic fluid (AF), two stem cell populations have been isolated: amniotic fluid mesenchymal stem cells (AFMSCs) and amniotic fluid stem (AFS) cells. It is possible that these cells may, given the easier accessibility of AF in comparison with other extra-embryonic tissues, hold much promise in regenerative medicine.",
keywords = "Amniotic fluid, Cell surface antigens, Fetal origin, Hematopoietic progenitor cells, Mesenchymal stem cells, Multilineage potential, Transcriptome",
author = "Mara Cananzi and Anthony Atala and {de Coppi}, Paolo",
year = "2013",
month = "11",
day = "4",
doi = "10.1016/B978-0-12-409503-8.00011-1",
language = "English (US)",
isbn = "9780124104273",
pages = "141--156",
booktitle = "Essentials of Stem Cell Biology: Third Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Stem Cells Derived from Amniotic Fluid

AU - Cananzi, Mara

AU - Atala, Anthony

AU - de Coppi, Paolo

PY - 2013/11/4

Y1 - 2013/11/4

N2 - In this chapter, we provide an overview of the potential advantages and disadvantages of different stem and progenitor cell populations identified to date in amniotic fluid, along with their properties and potential clinical applications. In the last ten years, placenta, fetal membranes (i.e., amnion and chorion), and amniotic fluid have been investigated as potentially uncontroversial sources of stem cells. Such tissues are typically discarded after delivery or are accessible during pregnancy through amniocentesis and chorionic villus sampling. Cell populations having multilineage differentiation potential and immunomodulatory properties have been isolated from the human placenta and fetal membranes, including human amniotic epithelial cells (hAECs), human amniotic mesenchymal stromal cells (hAMSCs), human chorionic mesenchymal stromal cells (hCMSCs), and human chorionic trophoblastic cells (hCTCs). From amniotic fluid (AF), two stem cell populations have been isolated: amniotic fluid mesenchymal stem cells (AFMSCs) and amniotic fluid stem (AFS) cells. It is possible that these cells may, given the easier accessibility of AF in comparison with other extra-embryonic tissues, hold much promise in regenerative medicine.

AB - In this chapter, we provide an overview of the potential advantages and disadvantages of different stem and progenitor cell populations identified to date in amniotic fluid, along with their properties and potential clinical applications. In the last ten years, placenta, fetal membranes (i.e., amnion and chorion), and amniotic fluid have been investigated as potentially uncontroversial sources of stem cells. Such tissues are typically discarded after delivery or are accessible during pregnancy through amniocentesis and chorionic villus sampling. Cell populations having multilineage differentiation potential and immunomodulatory properties have been isolated from the human placenta and fetal membranes, including human amniotic epithelial cells (hAECs), human amniotic mesenchymal stromal cells (hAMSCs), human chorionic mesenchymal stromal cells (hCMSCs), and human chorionic trophoblastic cells (hCTCs). From amniotic fluid (AF), two stem cell populations have been isolated: amniotic fluid mesenchymal stem cells (AFMSCs) and amniotic fluid stem (AFS) cells. It is possible that these cells may, given the easier accessibility of AF in comparison with other extra-embryonic tissues, hold much promise in regenerative medicine.

KW - Amniotic fluid

KW - Cell surface antigens

KW - Fetal origin

KW - Hematopoietic progenitor cells

KW - Mesenchymal stem cells

KW - Multilineage potential

KW - Transcriptome

UR - http://www.scopus.com/inward/record.url?scp=84942786689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942786689&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-409503-8.00011-1

DO - 10.1016/B978-0-12-409503-8.00011-1

M3 - Chapter

AN - SCOPUS:84942786689

SN - 9780124104273

SN - 9780124095038

SP - 141

EP - 156

BT - Essentials of Stem Cell Biology: Third Edition

PB - Elsevier Inc.

ER -